LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...

For people with chronic skin conditions, telehealth altered how they care for their skin and their bodies by removing ...

Alumis said its drug, envudeucitinib, met all primary and secondary endpoints in two Phase 3 trials in patients with moderate-to-severe plaque psoriasis. About 65% of patients achieved near-complete ...

Your flexible spending account (FSA) dollars are intended to be used on wellness-related costs like your prescriptions or doctor’s visits, but you can also spend smarter by shopping FSA-eligible skin ...

The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.

Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety ...

Wendy Smith Begolka, MBS, shares strategies to better meet the needs of patients with chronic inflammatory skin diseases.

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...

Newsweek discussed a viral social-media debate that has gained more than 15,000 upvotes with two dermatologists.

An itchy scalp could be a result of anything from dandruff to allergy to skin conditions like psoriasis. Here's how to get ...

Spread the loveAs the pharmaceutical industry continues to evolve, staying updated on significant advancements and market trends is crucial for marketers. March 19, 2026, brings pivotal updates that ...

Johnson & Johnson's novel oral peptide ICOTYDE wins FDA approval for plaque psoriasis, offering a convenient alternative to injectables with strong clinical results and major sales potential.